Hypercholesterolemia How-Tos

How To Apply What's New in Hypercholesterolemia
0.5 AMA PRA Category 1 Credit(s) 0.5 AANP Contact Hours 0.5 Pharmacology
Launch Date:
April 15, 2021
Expiration Date:
April 14, 2022

Primary Audience:

Cardiologists; nurse practitioners (NPs); physician assistants (PAs); and other clinicians engaged in the care of patients with hypercholesterolemia

Relevant Terms:

Hypercholesterolemia; dyslipidemia, ASCVD

Karol E. Watson, MD, PhD

Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Los Angeles, CA

Karol E. Watson, MD, PhD, FNLA, FACC, FAHA, is a Professor of Medicine/Cardiology and a board-certified, fulltime cardiologist at the Geffen School of Medicine at UCLA. She holds the John C. Mazziotta Term Chair in Medicine and was honored to be named Cardiologist of the Year by the California chapter of the American College of Cardiology (ACC) in 2017. Dr. Watson received her undergraduate degree from Stanford University, her Medical Degree from Harvard Medical School, magna cum laude, and her PhD in Physiology from UCLA. She completed a residency in Internal Medicine and a fellowship in Cardiology at UCLA, and continued there as part of the UCLA Specialty Training and Academic Research (STAR) program.

Currently, Dr. Watson is director of the UCLA Barbra Streisand Women’s Heart Health Program at UCLA, Co-Director of the UCLA Program in Preventive Cardiology, and director of the UCLA Fellowship Program in Cardiovascular Diseases. The American Society of Hypertension recognizes Dr. Watson as a Specialist in Hypertension.

She is a Principal Investigator for several large National Institutes of Health (NIH) studies, and serves on several NIH Steering committees. She is currently chair of the Clinical Chemistry and Clinical Toxicology Devices Panel of the Food and Drug Administration. Dr. Watson is past Vice President for the Association of Black Cardiologists (ABC); and immediate past chairperson of the scientific advisory board for Womenheart. She has received many honors including “America’s Top Physicians” designation from Black Enterprise magazine, a Super Doctors designation from “Tu Ciudad” and “Los Angeles” magazines, and in 2010 she was awarded a “Red Dress Award” from Woman’s Day magazine.

James A. Underberg, MS, MD, FACP, FNLA

James A. Underberg, MS, MD, FACP, FNLA
Clinical Assistant Professor of Medicine, New York University School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, New York, NY
Director, Bellevue Hospital Lipid Clinic, New York, NY
Past-President, National Lipid Association, Jacksonville, FL

Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU. He will be speaking October 3rd on Advances in Lipid Management: Evolving Strategies for Risk Reduction.

Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Past President of the National Lipid Association. He is a Fellow of the National Lipid Association and President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the Foundation of the National Lipid Association and the American Board of Clinical Lipidology.

Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.

Christie M. Ballantyne, MD

Chief, Sections of Cardiology & Cardiovascular Research
Professor of Medicine, Molecular & Human Genetics, and Molecular Physiology & Biophysics
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX

Christie Ballantyne, MD is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the AHA and to receive continuous funding from the NIH since in 1988 in basic research of leukocyte-endothelial interactions, translational research in biomarkers and clinical trials.

His many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017-2020 in the top 1% of researchers most cited. In 2019, Dr. Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for risk prediction of CV and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids.

With over 800 publications in the area of atherosclerosis, lipids and inflammation, Christie also serves on the Editorial Board for Circulation. Christie is the Chief of Cardiology and the Chief of Cardiovascular Research at Baylor College of Medicine. He is currently the Director for Cardiometabolic Disease Prevention at Baylor College of Medicine.

He received his MD from Baylor College of Medicine with internal medicine residency at The University of Texas Southwestern Medical School and cardiology fellowship at Baylor College of Medicine and an AHA fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

1. Utilize current and emerging lipid-lowering therapies to manage hypercholesterolemia, based on their different mechanisms of action and clinical trial data.
2. Incorporate strategies to reduce LDL-C in patients at high risk for ASCVD events by utilizing evidence-based medications, including combination therapy and pharmacologic and nonpharmacologic strategies, to reduce medication intolerance and to enhance patient adherence.

Program Overview

Although statins are the mainstay of hypercholesterolemia management, many patients do not achieve optimal LDL-C levels due to problems with adherence or lack of familiarity with available agents. Moreover, 7–29% of patients may not tolerate statin‐based treatment, which leads to medication non-adherence, increased incidence of atherosclerotic cardiovascular disease (ASCVD) events, and higher healthcare costs. With increasing numbers of non-statin lipid lowering therapies available and in development, it is critical for clinicians to be aware of the mechanisms of action and clinical trial data for these agents, as well as how best these can be utilized to manage hypercholesterolemia.

This 2-part educational series is designed to first enhance learner knowledge of new and emerging treatment options in the hypercholesterolemia space and then provide practical approaches for integrating knowledge learned in the clinic setting through a case-based presentation. This second activity in the series utilizes a series of case-based scenarios to help demonstrate how to assess cardiovascular risk status and incorporate the most appropriate strategies to improve adherence, reduce LDL, and optimize outcomes.

Association of Black Cardiologists Accreditation Statement

Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Association of Black Cardiologists Credit Designation Statement

Association of Black Cardiologists, Inc. designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AANP Accreditation Statement

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.5 contact hours.

How to claim credit

  1. Review the curriculum front matter.
  2. Participate in the curriculum.
  3. Complete the post-test and activity evaluation.
  4. You must score 65% or higher on the post-test to receive credit for this activity.


Policy on Faculty and Provider Disclosure

Accredited education provided by the National Association for Continuing Education (NACE) and ABC must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE and ABC accredited education are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest have been mitigated.

Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty and Planning Committee Disclosures

Christie M. Ballantyne has disclosed the following financial relationships:

  • Grant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, ADA
  • Consultant: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo.

James Underberg has disclosed the following financial relationships:

  • Consultant: Amgen
  • Advisory Board Member: Amgen, Alexion, Akcea, Amarin, Esperion, Novartis
  • Speakers Bureau: Aegerion, Amarin, Amgen, Amryt, Esperion
  • Speaking and Teaching: Medintelligence
  • Contracted Research: Amryt

Karol Watson has disclosed the following financial relationships:

  • Consultant: Amarin, Amgen, Boehringer Ingelheim, Esperion, Lilly
  • Advisory Board Member: Amarin, Amgen, Boehringer Ingelheim, Esperion, Lilly
  • Speakers Bureau: Boehringer Ingelheim, Lilly
  • Speaker: Amarin, Amgen, Boehringer Ingelheim, Esperion, Lilly

Gregg Sherman, MD, Activity Planning Committee, has no relevant conflicts of interest.

Michelle Frisch, MPH, Activity Planning Committee, has no relevant conflicts of interest.

Daniela Hiedra, Activity Planning Committee, has no relevant conflicts of interest.

Joshua Kilbridge, Medical Writer, has no relevant conflicts of interest.

Disclosure of Commercial Support

This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled/Investigational Uses of Products

The content of the presentations may include discussion of unapproved or investigational uses of product or devices.

Course format/medium: Internet Enduring Activity

Estimated time to complete the activity: 30 minutes


Supported Browsers:
Microsoft Edge
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.
Supported Phones & Tablets:
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
Chrome OS

Additional Recommendations and Requirements
Display Resolution & Color Depth Resolution
- 960 X 768 minimum
- 1024 X 768 recommended min.

Color Depth
- 8 bits (256 colors) minimum
- 16 bits (High colors) minimum
Audio - Microphone
- Speakers or headphones
- Audio recording support
Word Processing Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended.